Do we have enough evidence for recommending therapeutic apheresis for natalizumab-related progressive multifocal leukoencephalopathy patients? Comment on “Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for apheresis: The seventh special issue.”

Doriana Landi, Diego Centonze, Girolama Alessandra Marfia, Ruggero Capra, Cristina Scarpazza

Research output: Contribution to journalLetter

Original languageEnglish
Pages (from-to)450-451
Number of pages2
JournalJournal of Clinical Apheresis
Volume33
Issue number3
DOIs
Publication statusPublished - Jun 1 2018

ASJC Scopus subject areas

  • Hematology

Cite this